^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MP0250
i
Other names: MP0250, MP0250 DARPin drug, MP 0250, MP0250 designed repeat protein
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Molecular Partners
Drug class:
VEGF-A inhibitor, Hepatocyte growth factor inhibitor
Related drugs:
1m
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma. (PubMed, EJHaem)
These findings are in line with the results of recent trials testing new agents on comparable patient cohorts and provide initial evidence of clinical benefit for patients with refractory/relapsed MM treated with MP0250 in combination with bortezomib/dexamethasone. Further clinical evaluation in the emerging MM treatment landscape would be required to confirm the clinical potential of MP0250.
P1/2 data • Journal • Combination therapy
|
VEGFA (Vascular endothelial growth factor A) • HGF (Hepatocyte growth factor)
|
bortezomib • dexamethasone • MP0250
almost4years
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. (PubMed, J Clin Oncol)
MP0250 is a first-in-class DARPin drug candidate with suitable tolerability and appropriate pharmacokinetic properties for further development in combination with other anticancer therapies.
Clinical • P1 data • Journal
|
VEGFA (Vascular endothelial growth factor A)
|
MP0250
over4years
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC (clinicaltrials.gov)
P1b/2, N=8, Terminated, Molecular Partners AG | N=40 --> 8 | Trial completion date: Jul 2021 --> Apr 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2021 --> Aug 2019; Sponsor's decision
Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • MP0250
5years
The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs (ASH 2019)
Analysis of the preliminary efficacy results showed an encouraging ORR of 40%. Recruitment to this Phase 2 study is ongoing.
Clinical • P2 data
|
HGF (Hepatocyte growth factor)
|
bortezomib • MP0250
Share via
